LOS ANGELES, May 8 (Reuters) - Chelsea Therapeutics said on Monday it plans to acquire all rights previously belonging to Synergia Pharma for Droxidopa, a synthetic amino acid used in Japan to treat a type of hypotension associated with Parkinson’s Disease and other disorders.
